Criteria for evaluating improvement in schizophrenia in psychopharmacological research (with special reference to gamma endorphin fragments).
R Manchanda, S R Hirsch, T R Barnes
Index: Br. J. Psychiatry 153 , 354-8, (1988)
Full Text: HTML
Abstract
A review of treatment trials with DT gamma E revealed widely discrepant results. Relevant variables were the variety of measures employed for monitoring psychotic symptoms, and the different criteria used to judge the degree of improvement. The authors suggest a uniform outcome criterion for early trials of new treatments, which would generate more consistent and comparable results between studies, and give a stronger indication of the value of the treatment under test. When the data from the various treatment trials of DT gamma E were reanalysed, applying a uniform outcome criterion of improvement of a change of 80% or more on rating-scale score, the results were more consistent than would have been suspected from the original reports.
Related Compounds
Related Articles:
1985-01-01
[Immunogenetics 22(4) , 309-14, (1985)]
Des-tyrosine-gamma-endorphin effects on morphine analgesia in mice.
1993-01-01
[Gen. Pharmacol. 24(1) , 83-8, (1993)]
Short-lived effect of (Des-Tyr)-gamma-endorphin in schizophrenia.
1983-12-01
[Psychiatry Res. 10(4) , 243-52, (1983)]
1994-02-01
[J. Pharmacol. Exp. Ther. 268(2) , 1040-50, (1994)]
1986-10-01
[Int. Clin. Psychopharmacol. 1(4) , 303-13, (1986)]